Cardiology

Trials, guidelines and practice across cardiovascular medicine.

Wearable Hormone Monitoring Reveals Missed Cause of Hypertension

A wearable hormone monitor exposed nighttime aldosterone bursts in primary aldosteronism, a missed cause of hypertension that standard blood tests can overlook.

By Dr. Aishwarya N., MBBS · Oct 18, 2026 · 5 min read

Cardiology·Becker H

Equity in Generative AI for Cardiovascular Medicine Takes Center Stage

A JACC Advances review outlines how generative AI can widen or reduce inequities in cardiovascular care, and proposes…

Oct 18, 2026

Cardiology·Med Econ

Team-based hypertension care lowers blood pressure in high-risk patients

A team-based hypertension model at 36 FQHCs lowered systolic blood pressure and improved control in low-income patients over…

Oct 18, 2026

Cardiology·Med Econ

Cardiovascular Disease Overtakes Cancer in Hispanic Adults, AHA Warns

An AHA statement says cardiovascular disease now leads cancer in Hispanic adults, with earlier stroke, younger heart failure…

Oct 18, 2026

Cardiology·AHA

American Heart Association updates Life’s Essential 8 prevention guidance

American Heart Association fact sheets center Life’s Essential 8, preventive cardiovascular risk reduction, and updated guidance on blood…

Oct 18, 2026

Cardiology·MHRA

Heart Failure Burden Reaches 56 Million Cases Globally in 2023

Global heart failure cases reached 56 million in 2023, with major variation by age, region, and cause across…

Oct 18, 2026

Cardiology·ScienceDaily

ESC guidelines link heart disease and chronic kidney disease care

ESC and ERA guidelines urge earlier kidney screening in cardiovascular patients, pairing blood and urine testing with proven…

Oct 18, 2026

Cardiology·ScienceDaily

CRISPR Therapy Cuts LDL and Triglycerides for a Full Year

A one-time CRISPR infusion kept LDL cholesterol and triglycerides about half lower at one year in a first-in-human…

Oct 18, 2026

Cardiology·Becker H

Percutaneous Vegetation Aspiration During Lead Extraction Appears Feasible

A multicenter registry found percutaneous vegetation aspiration during transvenous lead extraction was feasible, with low aspiration-related complications but…

Oct 18, 2026

Cardiology·ScienceDaily

Atrial Fibrillation DOACs Cut Serious Events in Intermediate-Risk Patients

SINGLE-AF found apixaban or rivaroxaban lowered serious events in intermediate-risk atrial fibrillation without more major bleeding.

Oct 18, 2026

Cardiology

Trials, guidelines and practice across cardiovascular medicine.

In Brief The 5-minute rounds

New hypertension guideline lowers the treatment threshold to 130/80 mm Hg.
Phase 3 GLP-1 trial reports a 20% cut in major adverse cardiac events.
FDA clears a next-generation CAR-T therapy for relapsed lymphoma.
Meta-analysis links early mobilisation to shorter ICU length of stay.
Rapid guidance broadens empiric antibiotics for suspected sepsis.